Therapeutic solutions for neurodegeneration

There is currently no available treatment to slow down or stop diseases related to neurodegeneration. They affect tens of millions of persons worldwide.

Alzprotect designs and develops innovative therapeutic solutions for these diseases.

An exceptional therapeutic potential for the treatment of tauopathies – Progressive Supranuclear Palsy (PSP) and Alzheimer’s disease.

Schematic diagram of the action of AZP2006

Novel mechanism of action and promising therapeutic effects, acting on all known markers of neurodegeneration:
Amyloid beta peptide, Tau protein, Neuroinflammation, Oxidative stress.

Learn more about
AZP2006 molecule


Alzprotect strengthens its management team with the appointment of Dr. Olivier Defert as Chief Operating Officer

Lille (France), on 6th March 2023, Alzprotect, a biotechnology company focused on developing treatments for neurodegenerative diseases, announced the appointment of Dr. Olivier Defert as Chief Operating Officer (COO). Dr. Defert brings over 20 years of experience in the biotech and pharmaceutical industries, having held leadership positions in several companies. He is a highly qualified medicinal chemist who has held leadership positions at BioVersys SAS and Tarsier Pharma, among others. He foun...

Alzprotect announces the extension of Phase 2a clinical trial for the treatment of progressive supranuclear palsy (PSP)

Lille (France), 16 February 2023 – Alzprotect, the French biopharmaceutical company, announces the extension of its Phase 2a clinical trials of its drug candidate for Progressive Supranuclear Palsy (PSP), a neurodegenerative disease similar to Alzheimer's disease, which severely impacts balance, eye movements, cognition and, in the more advanced stages of the disease, the ability to swallow.

The initial C04 study (a randomised, blinded study comparing two doses of AZP2006 to placebo) showed pos...


All news